查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
真实世界证据（RWE）在塑造製药业数位化未来中的作用
市场调查报告书
商品编码
1764333

真实世界证据（RWE）在塑造製药业数位化未来中的作用

The Role of Real-World Evidence in Shaping Pharma's Digital Future
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入探讨了真实世界证据（RWE）在不断发展的製药领域中的关键作用，并重点关注了 RWE 在行业中日益成长的接受度和应用。报告深入分析了当前趋势，重点关注医疗资料的数位化以及人工智慧（AI）在 RWE 生成中的整合。报告还深入分析了阻碍 RWE 应用的障碍，包括资料品质挑战和地区接受度差异。

本报告也探讨了製药公司如何策略性地投资 RWE，以增强药物开发和上市能力。报告进一步展望了 RWE 的未来发展，并强调了数位医疗技术在改变患者护理和监管决策方面的潜力。

关键问题

  • 1.目前真实世界证据（RWE）的使用和接受度有哪些趋势？
  • 2.哪些障碍阻碍了RWE在製药业的应用与接受？
  • 3.医疗资料数位化如何影响RWE的生成？
  • 4.人工智慧（AI）在RWE生成中扮演什么角色？
  • 5.药厂如何投资RWE？
  • 6.未来RWE生成将如何发展？

重点公司

  • Flatiron Health
  • UCB
  • MedExcellence Solutions
  • IQVIA
  • Aetion

部分参加专家名单

  • Flatiron Health 临床资料管理负责人，美国
  • UCB 高级市场准入经理，澳洲
  • RWE 策略顾问，比利时
  • MedExcellence Solutions 董事总经理，比利时
  • 跨国製药公司 RWE 数位平台负责人，美国
  • 生物製药公司欧盟及数位资料转型负责人，英国

方法论

檔案报告是基于独立而简洁的分析，这些分析源自于专有产业研究以及对产业意见领袖的深入访谈。报告深入分析了製药企业高管需要了解的关键趋势和市场发展，以应对未来的机会和挑战。每份报告的重点都基于对二手文献的回顾和已发现的知识差距。基于这项初步研究，制定了基于证据、专家指导的讨论指南，以确保调查能够回答最重要的问题。此外，制定了严格的筛选标准，以确保受访者拥有就该主题发言所需的经验、知识和地位。

报告有何特别之处？

FirstWordReports 是值得信赖的行业领导者，致力于製药行业，为生物製药专业人士和决策者提供深入、可操作的洞察。深厚的行业知识使能够提供相关且有价值的洞察，帮助掌握新兴趋势，有效应对复杂挑战。凭藉广泛的研究以及来自顶尖专家和关键意见领袖（KOL）的独立、公正的见解，报告能够提供所需的准确性和可靠性。独家访谈和资料，以及持续的市场监测，让能够全面了解市场动态。报告涵盖40多个活跃的疾病领域，包括关键意见领袖洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入和其他领域问题的看法，有助于做出更明智的资料驱动决策，并在快速变化的行业中保持竞争力。

简介目录

This report delves into the pivotal role of real-world evidence (RWE) in the evolving pharmaceutical landscape, focusing on its increasing acceptance and application across the industry. It provides an in-depth analysis of current trends, highlighting the digitisation of healthcare data and the integration of artificial intelligence (AI) in RWE generation. Gain insights into the barriers that hinder RWE adoption, including data quality challenges and regional disparities in acceptance.

This report also explores how pharmaceutical companies are strategically investing in RWE to enhance drug development and market access. Additionally, it offers a forward-looking perspective on the future evolution of RWE, emphasising the potential for digital health technologies to transform patient care and regulatory decision making.

Key Questions Answered:

  • 1. What are the current trends in the use and acceptance of real-world evidence (RWE)?
  • 2. What barriers hinder the use and acceptance of RWE in the pharmaceutical industry?
  • 3. How is the digitisation of healthcare data impacting RWE generation?
  • 4. What role does artificial intelligence (AI) play in generating RWE?
  • 5. How are pharmaceutical companies investing in RWE?
  • 6. How will RWE generation evolve in the future?

Key Companies:

  • Flatiron Health
  • UCB
  • MedExcellence Solutions
  • IQVIA
  • Aetion

Partial List of Participating Experts:

  • Head, Clinical Data Management, Flatiron Health, US
  • Senior Market Access Manager, UCB, Australia
  • Strategic Consultant, RWE, Belgium
  • Managing Director, MedExcellence Solutions, Belgium
  • RWE Digital Platforms Lead, multinational pharma company, US
  • EU and Digital Data Transformation Lead, biopharma company, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.